

Irene Cassaniti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4016573/publications.pdf>

Version: 2024-02-01

66
papers

2,342
citations

236612

25
h-index

243296

44
g-index

76
all docs

76
docs citations

76
times ranked

5377
citing authors

#	ARTICLE	IF	CITATIONS
1	Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department. <i>Journal of Medical Virology</i> , 2020, 92, 1724-1727.	2.5	205
2	Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COVID19 REgistry (SMACORE). <i>Microorganisms</i> , 2020, 8, 695.	1.6	186
3	Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020. <i>Eurosurveillance</i> , 2020, 25, .	3.9	158
4	Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection. <i>Med</i> , 2021, 2, 281-295.e4.	2.2	153
5	Severe acute respiratory syndrome coronavirus 2 RNA contamination of inanimate surfaces and virus viability in a health care emergency unit. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1094.e1-1094.e5.	2.8	121
6	Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020. <i>Eurosurveillance</i> , 2020, 25, .	3.9	119
7	Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. <i>Nature</i> , 2021, 593, 424-428.	13.7	108
8	Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. <i>Nature Communications</i> , 2022, 13, 2670.	5.8	108
9	SARS Cov-2 infection in a renal-transplanted patient: A case report. <i>American Journal of Transplantation</i> , 2020, 20, 1882-1884.	2.6	76
10	Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant. <i>BMC Medicine</i> , 2022, 20, 102.	2.3	67
11	EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. <i>International Journal of Infectious Diseases</i> , 2021, 104, 315-319.	1.5	66
12	Immunity to SARS-CoV-2 up to 15 months after infection. <i>IScience</i> , 2022, 25, 103743.	1.9	56
13	Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1635-1638.	0.5	55
14	SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers. <i>Nature Communications</i> , 2021, 12, 6032.	5.8	55
15	Lack of SARS-CoV-2 RNA environmental contamination in a tertiary referral hospital for infectious diseases in Northern Italy. <i>Journal of Hospital Infection</i> , 2020, 105, 474-476.	1.4	51
16	Emergency Department and Out-of-Hospital Emergency System (112-AREU 118) integrated response to Coronavirus Disease 2019 in a Northern Italy centre. <i>Internal and Emergency Medicine</i> , 2020, 15, 825-833.	1.0	50
17	SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1029-1034.	2.8	49
18	West Nile or Usutu Virus? A Three-Year Follow-Up of Humoral and Cellular Response in a Group of Asymptomatic Blood Donors. <i>Viruses</i> , 2020, 12, 157.	1.5	44

#	ARTICLE	IF	CITATIONS
19	Dynamic angiotensin-converting enzyme 2 assessment predicts survival and chronic course in hospitalized patients with COVID-19. <i>Blood Advances</i> , 2021, 5, 662-673.	2.5	42
20	Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection. <i>Stem Cells Translational Medicine</i> , 2021, 10, 636-642.	1.6	40
21	Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection. <i>American Journal of Transplantation</i> , 2021, 21, 1622-1628.	2.6	35
22	A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study. <i>ESMO Open</i> , 2021, 6, 100272.	2.0	34
23	Human Cytomegalovirus-Specific Memory CD4+ T-Cell Response and Its Correlation With Virus Transmission to the Fetus in Pregnant Women With Primary Infection. <i>Clinical Infectious Diseases</i> , 2017, 65, 1659-1665.	2.9	33
24	Rapid response to COVID-19 outbreak in Northern Italy: how to convert a classic infectious disease ward into a COVID-19 response centre. <i>Journal of Hospital Infection</i> , 2020, 105, 477-479.	1.4	31
25	A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice. <i>European Journal of Immunology</i> , 2021, 51, 1774-1784.	1.6	30
26	Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 301.e1-301.e8.	2.8	28
27	SARS-CoV-2 viability on different surfaces after gaseous ozone treatment: a preliminary evaluation. <i>Journal of Hospital Infection</i> , 2021, 110, 33-36.	1.4	24
28	Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study. <i>Clinical Infectious Diseases</i> , 2023, 76, e426-e438.	2.9	23
29	Effect of a Third Dose of SARS-CoV-2 mRNA BNT162b2 Vaccine on Humoral and Cellular Responses and Serum Anti-HLA Antibodies in Kidney Transplant Recipients. <i>Vaccines</i> , 2022, 10, 921.	2.1	21
30	Incidence of SARS-CoV-2 infection in health care workers from Northern Italy based on antibody status: immune protection from secondary infection- A retrospective observational case-controlled study. <i>International Journal of Infectious Diseases</i> , 2021, 109, 199-202.	1.5	20
31	Machine Learning-based Voice Assessment for the Detection of Positive and Recovered COVID-19 Patients. <i>Journal of Voice</i> , 2021, , .	0.6	20
32	Macrophages and Monocytes: "Trojan Horses" in COVID-19. <i>Viruses</i> , 2021, 13, 2178.	1.5	18
33	Evaluation of EBV- and HCMV-Specific T Cell Responses in Systemic Lupus Erythematosus (SLE) Patients Using a Normalized Enzyme-Linked Immunospot (ELISPOT) Assay. <i>Journal of Immunology Research</i> , 2019, 2019, 1-12.	0.9	14
34	Emergence of Letermovir-resistant HCMV UL56 mutant during rescue treatment in a liver transplant recipient with ganciclovir-resistant infection HCMV: a case report. <i>BMC Infectious Diseases</i> , 2021, 21, 994.	1.3	11
35	Clinical, virological and immunological evolution of the olfactory and gustatory dysfunction in COVID-19. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2022, 43, 103170.	0.6	11
36	Impact of immunosuppressive treatment on the immunogenicity of mRNA COVID-19 vaccine in vulnerable patients with giant cell arteritis. <i>Rheumatology</i> , 2022, 61, 870-872.	0.9	10

#	ARTICLE	IF	CITATIONS
37	SARS-CoV-2 positivity in rectal swabs: implication for possible transmission. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 22, 754-755.	0.9	9
38	Seroprevalence of SARS-CoV-2 in blood donors from the Lodi Red Zone and adjacent Lodi metropolitan and suburban area. <i>Clinical Microbiology and Infection</i> , 2021, 27, 914.e1-914.e4.	2.8	9
39	Immune Response to BNT162b2 in Solid Organ Transplant Recipients: Negative Impact of Mycophenolate and High Responsiveness of SARS-CoV-2 Recovered Subjects against Delta Variant. <i>Microorganisms</i> , 2021, 9, 2622.	1.6	9
40	Molecular Epidemiology of Rhinovirus/Enterovirus and Their Role on Cause Severe and Prolonged Infection in Hospitalized Patients. <i>Microorganisms</i> , 2022, 10, 755.	1.6	9
41	Memory T cells specific for HBV enumerated by a peptide-based cultured enzyme-linked immunospot assay in healthy HBV-vaccinated subjects. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2927-2933.	1.4	8
42	CD4 T Cell Determinants in West Nile Virus Disease and Asymptomatic Infection. <i>Frontiers in Immunology</i> , 2020, 11, 16.	2.2	7
43	Thirteen Years of Phleboviruses Circulation in Lombardy, a Northern Italy Region. <i>Viruses</i> , 2021, 13, 209.	1.5	7
44	Human Cytomegalovirus and Epstein-Barr virus specific immunity in patients with ulcerative colitis. <i>Clinical and Experimental Medicine</i> , 2021, 21, 379-388.	1.9	7
45	Photopheresis Abates the Anti-HLA Antibody Titer and Renal Failure Progression in Chronic Antibody-Mediated Rejection. <i>Biology</i> , 2021, 10, 547.	1.3	7
46	Characterization of Varicella-Zoster (VZV) Specific T Cell Response in Healthy Subjects and Transplanted Patients by Using Enzyme Linked Immunospot (ELISpot) Assays. <i>Vaccines</i> , 2021, 9, 875.	2.1	7
47	Immunosuppressive treatments selectively affect the humoral and cellular response to SARS-CoV-2 in vaccinated patients with vasculitis. <i>Rheumatology</i> , 2023, 62, 726-734.	0.9	7
48	Outbreak of measles genotype H1 in Northern Italy originated from a case imported from Southeast Asia, 2017. <i>Clinical Microbiology and Infection</i> , 2019, 25, 526-528.	2.8	5
49	SARS-CoV-2 Virologic and Immunologic Correlates in Patients with Olfactory and Taste Disorders. <i>Microorganisms</i> , 2020, 8, 1052.	1.6	5
50	Both SARS-CoV-2 infection and vaccination in pregnancy elicited neutralizing antibodies in pregnant women and newborns. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1708-1709.	2.8	5
51	Herpes zoster in patients with solid tumors treated with immune checkpoint inhibitors. <i>Immunotherapy</i> , 2022, 14, 389-393.	1.0	5
52	Low risk for SARS-CoV2 symptomatic infection and early complications in paediatric patients during the ongoing COVID19 epidemics in Lombardy. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1569-1571.	2.8	4
53	Detection of the SARS-CoV-2 in different biologic specimens from positive patients with COVID-19, in Northern Italy. <i>Pediatric Allergy and Immunology</i> , 2020, 31, 72-74.	1.1	4
54	Impaired virus-specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib. <i>Hematological Oncology</i> , 2020, 38, 554-559.	0.8	4

#	ARTICLE	IF	CITATIONS
55	SARS-CoV-2 variants inactivation of plasma units using a riboflavin and ultraviolet light-based photochemical treatment. <i>Transfusion and Apheresis Science</i> , 2022, 61, 103398.	0.5	4
56	Zika Virus Infection in Pregnancy: Advanced Diagnostic Approaches in Dengue-Naive and Dengue-Experienced Pregnant Women and Possible Implication for Cross-Reactivity and Cross-Protection. <i>Microorganisms</i> , 2020, 8, 56.	1.6	3
57	Evaluation of the Neutralizing Antibodies Response against 14 SARS-CoV-2 Variants in BNT162b2 Vaccinated Naïve and COVID-19 Positive Healthcare Workers from a Northern Italian Hospital. <i>Vaccines</i> , 2022, 10, 703.	2.1	3
58	Dengue Virus-Specific Humoral and T Cellular Immune Response in Italian Residents and Travelers Returning from Endemic Areas. <i>Vector-Borne and Zoonotic Diseases</i> , 2020, 20, 295-302.	0.6	2
59	Authors'™ response: COVID-19: how accurate are seroprevalence studies?. <i>Eurosurveillance</i> , 2020, 25, .	3.9	2
60	Performance of Whole Blood Stimulation Assays for the Quantification of SARS-CoV-2 Specific T-Cell Response: A Cross-Sectional Study. <i>Diagnostics</i> , 2022, 12, 1509.	1.3	2
61	mRNA BNT162b Vaccine Elicited Higher Antibody and CD4+ T-Cell Responses than Patients with Mild COVID-19. <i>Microorganisms</i> , 2022, 10, 1250.	1.6	2
62	Evaluation of Virus-Specific T Cell Responses in Patients Affected with Myeloproliferative Neoplasms Treated with Ruxolitinib. <i>Blood</i> , 2019, 134, 1660-1660.	0.6	1
63	Chemotherapy to induce T-cell subpopulation changes in advanced breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12562-e12562.	0.8	1
64	Normalizing ELISPOT to quantify human cytomegalovirus (HCMV) and Epstein Barr-virus (EBV) specific T-cell response in kidney transplant recipients. <i>Journal of Clinical Virology</i> , 2016, 82, S99.	1.6	0
65	P.05.5: Human Cytomegalovirus- and Epstein-Barr Virus-Specific T-Cell Immunity in Patients with Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2017, 49, e157-e158.	0.4	0
66	Immunological Aspects of Human Papilloma Virus-Related Cancers Always Says, "œl Am like a Box of Complexity, You Never Know What You Are Gonna Get". <i>Vaccines</i> , 2022, 10, 731.	2.1	0